Prolymphocytic Leukemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PRL017 MIFTS: 47	Prolymphocytic Leukemia Categories: Blood diseases, Cancer diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Prolymphocytic Leukemia

MalaCards integrated aliases for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia ¹² ⁷³ ¹⁵ ⁷⁰

Leukemia, Prolymphocytic ⁴⁴

Leukemia Prolymphocytic ⁵⁴

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1039

MeSH ⁴⁴ D015463

NCIt ⁵⁰ C3181

SNOMED-CT ⁶⁷ 110006004

UMLS ⁷⁰ C0023486

Sources

Summaries for Prolymphocytic Leukemia

MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to b cell prolymphocytic leukemia and t-cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is MTCP1 (Mature T Cell Proliferation 1), and among its related pathways/superpathways are IL-2 Pathway and Endometrial cancer. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and Decreased human cytomegalovirus (HCMV) strain AD169 replication

Wikipedia : ⁷³ Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Sources

Related Diseases for Prolymphocytic Leukemia

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)

#	Related Disease	Score	Top Affiliating Genes
1	b cell prolymphocytic leukemia	32.0	ZAP70 TP53 MYC FCER2 CD5 CD38
2	t-cell prolymphocytic leukemia	31.6	TCL1A MYC MTCP1 JAK3 JAK1 HLA-S
3	t-cell lymphoblastic leukemia/lymphoma	30.5	ZAP70 TCL1A MYC MTCP1 CD7 CCND1
4	anemia, autoimmune hemolytic	30.5	ZAP70 CD52 CD5 CD19
5	adult t-cell leukemia	30.4	TP53 MYC JAK3 CD7
6	ataxia-telangiectasia	30.3	TP53 TCL1A MTCP1 ATM ABL1
7	adult lymphoma	30.2	MYC CD5 CD19
8	pancytopenia	30.2	TP53 CD7 CD5 CD19
9	hairy cell leukemia	30.1	TP53 CD52 CD5 CD38 CCND1 ADA
10	plasma cell leukemia	30.0	MYC CD38 CCND1
11	rare tumor	30.0	FCER2 CR2
12	leukemia	29.9	TP53 TCL1A MYC MTCP1 JAK3 JAK1
13	lymphoblastic lymphoma	29.9	TP53 MYC CD7 CD5
14	leukemia, chronic lymphocytic 2	29.9	ZAP70 FCER2 CD5 CD38 ATM
15	plasmacytoma	29.9	MYC CD5 CD38 CCND1
16	precursor t-cell acute lymphoblastic leukemia	29.9	TCL1A MYC CD7 ABL1
17	diffuse large b-cell lymphoma	29.8	TP53 MYC CD5 CD38 CD19 CCND1
18	t-cell adult acute lymphocytic leukemia	29.7	TP53 JAK3 CD7 CD52 CD5
19	richter's syndrome	29.7	ZAP70 TP53 MYC CD5 CD38 CD19
20	sezary's disease	29.5	TP53 MYC JAK3 CD7 CD52 CD5
21	mantle cell lymphoma	29.5	TP53 TCL1A MYC CD52 CD5 CD19
22	burkitt lymphoma	29.4	TP53 TCL1A MYC FCER2 CR2 CD19
23	peripheral t-cell lymphoma	29.3	TP53 TCL1A JAK3 CD5 CD38 CD19
24	lymphoma	29.3	TP53 TCL1A MYC CR2 CD5 CD38
25	cll/sll	29.2	ZAP70 TP53 CD5 CD38 CD19 CCND1
26	myeloma, multiple	29.2	TP53 MYC CD5 CD38 CD19 CCND1
27	t-cell acute lymphoblastic leukemia	29.1	TP53 MYC JAK3 JAK1 CD38 ATM
28	b-cell lymphoma	29.0	ZAP70 TP53 TCL1A MYC FCER2 CR2
29	lymphoma, mucosa-associated lymphoid type	29.0	ZAP70 TP53 MYC CR2 CD5 CD19
30	leukemia, acute lymphoblastic	28.5	ZAP70 TP53 TCL1A MYC JAK3 JAK1
31	leukemia, chronic lymphocytic	28.3	ZAP70 TP53 TCL1A MYC FCER2 CR2
32	leukemia, acute myeloid	28.2	TP53 MYC JAK3 JAK1 CD7 CD5
33	lymphoma, non-hodgkin, familial	27.9	TP53 TCL1A MYC FCER2 CR2 CD7
34	splenic manifestation of prolymphocytic leukemia	11.1
35	splenomegaly	10.8
36	leukemia, t-cell, chronic	10.7
37	lymphoproliferative syndrome	10.6
38	chromosomal triplication	10.6
39	lymphoma aids related	10.4	TCL1A MYC
40	endocrine exophthalmos	10.4	CD5 ATM
41	appendix lymphoma	10.4	MYC CD5
42	telangiectasis	10.4
43	intravascular large b-cell lymphoma	10.3	MYC CD5
44	parapsoriasis	10.3	CD7 CD5
45	listeria meningitis	10.3	CD52 ADA
46	immunodeficiency 19	10.3	ZAP70 ADA
47	anal carcinoma in situ	10.3	TP53 MYC
48	ataxia and polyneuropathy, adult-onset	10.3
49	graft-versus-host disease	10.3
50	refractory hematologic cancer	10.3	CD38 CD19

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:

Sources

Symptoms & Phenotypes for Prolymphocytic Leukemia

GenomeRNAi Phenotypes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.23	ATM CCND1 CD5 CD52 CD7 JAK3
2	Decreased human cytomegalovirus (HCMV) strain AD169 replication	GR00248-A	9.13	ATM JAK3 ZAP70

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.15	ABCB4 ABL1 ADA ATM CCND1 CD19
2	hematopoietic system	MP:0005397	10.06	ABCB4 ABL1 ADA ATM CCND1 CD19
3	endocrine/exocrine gland	MP:0005379	10.03	ABCB4 ABL1 ADA ATM CCND1 CD38
4	digestive/alimentary	MP:0005381	9.97	ABCB4 ABL1 ADA CCND1 CD19 FCER2
5	immune system	MP:0005387	9.86	ABCB4 ABL1 ADA ATM CCND1 CD19
6	normal	MP:0002873	9.28	ABL1 ADA CCND1 CD19 CD5 JAK1

Sources

Drugs & Therapeutics for Prolymphocytic Leukemia

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ketamine

Approved, Vet_approved

Phase 3

6740-88-1

3821

Dalteparin

Approved

Phase 3

9005-49-6

Tinzaparin

Approved

Phase 3

9041-08-1, 9005-49-6

25244225

Dextromethorphan

Approved

Phase 3

125-71-3

5360696 5362449

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 498142 38904

Caspofungin

Approved

Phase 3

179463-17-3, 162808-62-0

468682 2826718

Cladribine

Approved, Investigational

Phase 3

4291-63-8

20279

Iron

Approved

Phase 3

7439-89-6

23925 29936

Darbepoetin alfa

Approved, Investigational

Phase 3

209810-58-2, 11096-26-7

Amphotericin B

Approved, Investigational

Phase 3

1397-89-3

14956 5280965

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Ginseng

Approved, Investigational, Nutraceutical

Phase 3

50647-08-0

Pancreatic Polypeptide

Investigational

Phase 3

59763-91-6

Neurotransmitter Agents

Phase 3

Anesthetics, Dissociative

Phase 3

Analgesics

Phase 3

Cola

Phase 3

Heparin, Low-Molecular-Weight

Phase 3

Narcotics

Phase 3

Excitatory Amino Acid Antagonists

Phase 3

Analgesics, Opioid

Phase 3

Epoetin alfa

Phase 3

113427-24-0

Hematinics

Phase 3

Antiparasitic Agents

Phase 3

Antiprotozoal Agents

Phase 3

Liver Extracts

Phase 3

Amebicides

Phase 3

Liposomal amphotericin B

Phase 3

Anesthetics

Phase 3

Anesthetics, Intravenous

Phase 3

Anesthetics, General

Phase 3

ferric gluconate

Phase 3

Iron Supplement

Phase 3

Mitoxantrone

Approved, Investigational

Phase 2

65271-80-9

4212

Cytarabine

Approved, Investigational

Phase 1, Phase 2

147-94-4

6253

Ifosfamide

Approved

Phase 1, Phase 2

3778-73-2

3690

Docetaxel

Approved, Investigational

Phase 1, Phase 2

114977-28-5

148124

Irinotecan

Approved, Investigational

Phase 2

100286-90-6, 97682-44-5

60838

Mesna

Approved, Investigational

Phase 2

3375-50-6

598

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Pentostatin

Approved, Investigational

Phase 2

53910-25-1

439693 40926

Aldesleukin

Approved

Phase 2

85898-30-2, 110942-02-4

Carmustine

Approved, Investigational

Phase 2

154-93-8

2578

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Vidarabine

Approved, Investigational

Phase 1, Phase 2

24356-66-9

21704 32326

ofatumumab

Approved

Phase 1, Phase 2

679818-59-8

6918251

Auranofin

Approved, Investigational

Phase 2

34031-32-8

6918453 6333901

Atorvastatin

Approved

Phase 2

134523-00-5

60823

Interventional clinical trials:

(show top 50) (show all 189)

#	Name	Status	NCT ID	Phase	Drugs
1	Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB	Unknown status	NCT00020865	Phase 3	cefepime hydrochloride;levofloxacin
2	A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients	Unknown status	NCT01316744	Phase 3	ketamine hydrochloride
3	A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters	Completed	NCT00006083	Phase 3	Fragmin
4	A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients	Completed	NCT00003687	Phase 3	dextromethorphan hydrobromide;morphine sulfate
5	Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia	Completed	NCT00003816	Phase 2, Phase 3	busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
6	Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia	Completed	NCT00003746	Phase 3	2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
7	A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy	Completed	NCT00070382	Phase 3	darbepoetin alfa;epoetin alfa
8	A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia	Completed	NCT00008359	Phase 3	caspofungin acetate;liposomal amphotericin B
9	Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer	Completed	NCT00006348	Phase 3	ondansetron
10	A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials	Completed	NCT00003938	Phase 3	liposomal amphotericin B
11	Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT)	Completed	NCT00750009	Phase 3
12	A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia	Completed	NCT00661999	Phase 3	sodium ferric gluconate complex in sucrose
13	Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain.	Completed	NCT00666211	Phase 3
14	The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study	Completed	NCT00719563	Phase 3	American ginseng
15	A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
16	A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
17	Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma	Unknown status	NCT02819583	Phase 1, Phase 2
18	Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma	Unknown status	NCT02851589	Phase 1, Phase 2
19	Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma	Unknown status	NCT02742727	Phase 1, Phase 2
20	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma	Unknown status	NCT02892695	Phase 1, Phase 2
21	Clinical Study of CD19/CD22 Tan CAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas	Unknown status	NCT03185494	Phase 1, Phase 2
22	Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma	Unknown status	NCT01735604	Phase 1, Phase 2
23	Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells	Completed	NCT00006252	Phase 2	fludarabine phosphate;Cyclophosphamide;G-CSF
24	Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia	Completed	NCT00278213	Phase 2	cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
25	Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy	Completed	NCT00010283	Phase 1, Phase 2	beclomethasone dipropionate
26	Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia	Completed	NCT00006379	Phase 2	cyclophosphamide;fludarabine phosphate
27	Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen	Completed	NCT00005804	Phase 2	cyclophosphamide
28	A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies	Completed	NCT00003406	Phase 1, Phase 2	carboplatin;docetaxel;ifosfamide
29	Phase II Study of High Dose Cyclophosphamide and Rituximab in Low Grade and Mantle Cell Lymphoma	Completed	NCT00278161	Phase 2	Cyclophosphamide
30	Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy	Completed	NCT00255749	Phase 2
31	A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)	Completed	NCT00110045	Phase 2	caspofungin acetate
32	Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation	Completed	NCT00053196	Phase 2	busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
33	Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) in Newly Diagnosed and Relapsed Indolent Lymphoproliferative Malignancies	Completed	NCT00005626	Phase 2	Irinotecan
34	RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa	Completed	NCT00416624	Phase 2	darbepoetin alfa;epoetin alfa
35	A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas	Completed	NCT00416351	Phase 1, Phase 2	clofarabine
36	Phase II Multicenter Trial Of Pentostatin and Rituximab In Patients With Previously Treated and Untreated Low Grade B-Cell Non-Hodgkin's Lymphoma (NHL) Including Chronic Lymphocytic Leukemia (CLL)	Completed	NCT00026351	Phase 2	pentostatin
37	Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen	Completed	NCT00448357	Phase 1, Phase 2	busulfan;fludarabine phosphate;tacrolimus;methotrexate
38	Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen	Completed	NCT00448201	Phase 2	busulfan;fludarabine phosphate;methotrexate;tacrolimus
39	OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER	Completed	NCT00002504	Phase 2
40	A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies	Completed	NCT00782379	Phase 2	busulfan;cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
41	Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study	Completed	NCT00823524	Phase 1, Phase 2
42	Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial	Completed	NCT00060424	Phase 2	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
43	Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	Completed	NCT01008462	Phase 2	Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
44	Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia	Completed	NCT01186640	Phase 2	Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
45	A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial	Completed	NCT00005803	Phase 1, Phase 2	Carmustine;Cyclophosphamide;Cyclosporine;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil
46	A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL	Completed	NCT00464633	Phase 2	alvocidib
47	A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial	Completed	NCT01251575	Phase 2	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
48	Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas	Completed	NCT03097770	Phase 1, Phase 2
49	Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen	Completed	NCT00309842	Phase 2	cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
50	Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies	Completed	NCT01093586	Phase 2	busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Sources

Genetic Tests for Prolymphocytic Leukemia

Sources

Anatomical Context for Prolymphocytic Leukemia

MalaCards organs/tissues related to Prolymphocytic Leukemia:

⁴⁰

T Cells, Bone, Bone Marrow, Myeloid, B Cells, Liver, Skin

Sources

Publications for Prolymphocytic Leukemia

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 857)

#	Title	Authors	PMID	Year
1	[CD5-positive B-cell prolymphocytic leukemia]. ⁵⁴ ⁶¹	Inoue T...Yoshida T	20134145	2010
2	Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. ⁵⁴ ⁶¹	Nowak D...Koeffler HP	19278963	2009
3	Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. ⁵⁴ ⁶¹	Le Toriellec E...Stern MH	18073348	2008
4	High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. ⁵⁴ ⁶¹	Herling M...Jones D	17890451	2008
5	IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). ⁵⁴ ⁶¹	Del Giudice I...Catovsky D	16642047	2006
6	D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia. ⁶¹ ⁵⁴	Meyerson HJ...Kaplan D	16393687	2006
7	Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. ⁶¹ ⁵⁴	Hiromura M...Noguchi M	15459205	2004
8	Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. ⁶¹ ⁵⁴	Admirand JH...Medeiros LJ	15133473	2004
9	ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. ⁵⁴ ⁶¹	Gronbaek K...Guldberg P	12149228	2002
10	Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif. ⁶¹ ⁵⁴	Bradshaw PS...Yuille MR	11821961	2002
11	Structure of murine Tcl1 at 2.5 A resolution and implications for the TCL oncogene family. ⁵⁴ ⁶¹	Petock JM...Weber IT	11679718	2001
12	TCL1 is activated by chromosomal rearrangement or by hypomethylation. ⁶¹ ⁵⁴	Yuille MR...Catovsky D	11241786	2001
13	Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. ⁵⁴ ⁶¹	Narducci MG...Russo G	10786666	2000
14	Aberrant splicing of the ATM gene associated with shortening of the intronic mononucleotide tract in human colon tumor cell lines: a novel mutation target of microsatellite instability. ⁵⁴ ⁶¹	Ejima Y...Sasaki MS	10738255	2000
15	Role of TCL1 and ALL1 in human leukemias and development. ⁵⁴ ⁶¹	Croce CM	10197596	1999
16	Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. ⁶¹ ⁵⁴	Gritti C...Stern MH	9657733	1998
17	Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL. ⁶¹ ⁵⁴	Luo L...Vorechovsky I	9622061	1998
18	Inactivation of the ATM gene in T-cell prolymphocytic leukemias. ⁵⁴ ⁶¹	Stoppa-Lyonnet D...Stern MH	9573030	1998
19	Solution structure of the recombinant human oncoprotein p13MTCP1. ⁵⁴ ⁶¹	Yang YS...Roumestand C	9691281	1998
20	Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. ⁵⁴ ⁶¹	Hoh F...van Tilbeurgh H	9519406	1998
21	Alternative origin of p13MTCP1-encoding transcripts in mature T-cell proliferations with t(X;14) translocations. ⁶¹ ⁵⁴	Gritti C...Stern MH	9315101	1997
22	Perforin-positive leukemic cell infiltration in the aortic tissue of a patient with T-cell prolymphocytic leukemia. ⁶¹ ⁵⁴	Seko Y...Yazaki Y	8971584	1996
23	Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. ⁵⁴ ⁶¹	Madani A...Stern MH	8634440	1996
24	Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32). ⁶¹ ⁵⁴	Kobayashi H...Motokura T	7497446	1995
25	B-cell prolymphocytic leukemia expressing CD13 antigen. ⁶¹ ⁵⁴	Matsushita A...Takahashi T	7524729	1994
26	Burkitt-like mutations in the c-myc gene locus in prolymphocytic leukemia. ⁵⁴ ⁶¹	Brennscheidt U...Herrmann F	8182948	1994
27	Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. ⁵⁴ ⁶¹	Williams ME...Swerdlow SH	8172823	1994
28	Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2'-deoxycoformycin. ⁵⁴ ⁶¹	Johnston JB...Begleiter A	1528066	1992
29	Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. ⁶¹ ⁵⁴	Nooter K...Baas F	2323839	1990
30	Purine metabolism enzymes and immunological phenotype in chronic B-cell malignancies: chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia. ⁶¹ ⁵⁴	Babusikova O...Ujhazy P	2125699	1990
31	Ibrutinib-induced acute kidney injury via interstitial nephritis. ⁶¹	Markoth C...Matyus J	33567947	2021
32	Shikonin Derivatives from Onsoma visianii Decrease Expression of Phosphorylated STAT3 in Leukemia Cells and Exert Antitumor Activity. ⁶¹	Todorovic Z...Arsenijevic N	33807148	2021
33	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. ⁶¹	Hampel PJ...Ding W	33654067	2021
34	T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches. ⁶¹	Colon Ramos A...Gupta S	33728186	2021
35	Cutaneous Presentation of T-Cell Prolymphocytic Leukemia Mimicking Dermatomyositis. ⁶¹	Ingrasci G...Yosipovitch G	33606377	2021
36	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia ⁶¹	Kornauth C...Staber PB	33626863	2021
37	The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia. ⁶¹	Erkeland SJ...Langerak AW	33596640	2021
38	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. ⁶¹	Herbaux C...Davids MS	33598678	2021
39	T-cell prolymphocytic leukemia: Insidious onset followed by aggressive course with cutaneous involvement. ⁶¹	Zanelli M...Ascani S	33599388	2021
40	T-cell Prolymphocytic Leukemia, Cerebriform Variant. ⁶¹	Carvalho J...Ribeiro C	33732560	2021
41	Optic nerve biopsy in leukemic infiltrative optic neuropathy: a case report and review of the literature. ⁶¹	Chamberlain PD...Al-Zubidi N	33557696	2021
42	Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia. ⁶¹	Shumilov E...Wulf GG	32259827	2021
43	What to Look Out for when Transplanting T-Cell Prolymphocytic Leukemia. ⁶¹	Wahnschaffe L...Herling M	32369824	2021
44	A Complex Karyotype in a 68-Year-Old Patient With T-PLL. ⁶¹	Yang GE...Tirado CA	33684910	2021
45	T-Cell Prolymphocytic Leukemia: Long-Term Remissions Challenging! ⁶¹	Sellner L	32392564	2021
46	An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia. ⁶¹	Bell S...Pelayo M	33533282	2021
47	Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia. ⁶¹	Johansson P...Durig J	32875608	2020
48	Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma. ⁶¹	Andersen MA...Niemann CU	32970500	2020
49	Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. ⁶¹	Oberbeck S...Herling M	33301031	2020
50	Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways. ⁶¹	Braun T...Herling M	33543866	2020

Sources

Genes for Prolymphocytic Leukemia

Genes related to Prolymphocytic Leukemia (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MTCP1	Mature T Cell Proliferation 1	Protein Coding	44.65	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Functions (show sections)	9520380 9691281 10959629 (more) 11679718 9315101 9519406
2	ATM	ATM Serine/Threonine Kinase	Protein Coding	41.62	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Variants (show sections)	9573030 10738255 12149228 (more) 18073348 19278963 11821961 9622061
3	TCL1A	TCL1 Family AKT Coactivator A	Protein Coding	27.47	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9691281 8634440 9657733 (more) 10959629 11241786 17890451 10786666 11679718 9520462 9519406 10197596 15459205
4	CD5	CD5 Molecule	Protein Coding	23.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	20134145
5	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	19.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8182948
6	ZAP70	Zeta Chain Of T Cell Receptor Associated Protein Kinase 70	Protein Coding	18.88	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15133473 16642047
7	CD38	CD38 Molecule	Protein Coding	18.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16642047
8	ADA	Adenosine Deaminase	Protein Coding	16.42	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	2125699 1528066
9	CD52	CD52 Molecule	Protein Coding	14.38	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	HLA-S	Major Histocompatibility Complex, Class I, S (Pseudogene)	Pseudogene	14.19	Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8971584
11	CD7	CD7 Molecule	Protein Coding	13.89	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	ABCB4	ATP Binding Cassette Subfamily B Member 4	Protein Coding	13.44	Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	2323839
13	CD19	CD19 Molecule	Protein Coding	13.15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	JAK3	Janus Kinase 3	Protein Coding	13.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	FCER2	Fc Fragment Of IgE Receptor II	Protein Coding	12.85	Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	10911380
16	CCND1	Cyclin D1	Protein Coding	12.8	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	16393687 8172823 7497446 (more) 9548443
17	JAK1	Janus Kinase 1	Protein Coding	12.43	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	TP53	Tumor Protein P53	Protein Coding	12.36	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	CR2	Complement C3d Receptor 2	Protein Coding	11.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	11.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	11.52	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	11.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Prolymphocytic Leukemia

Sources

Expression for Prolymphocytic Leukemia

Search GEO for disease gene expression data for Prolymphocytic Leukemia.

Sources

Pathways for Prolymphocytic Leukemia

Pathways related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 44)

#	Super pathways	Score	Top Affiliating Genes
1	IL-2 Pathway ⁶³ Show member pathways ErbB Family Pathway ⁶³ ErbB2-ErbB3 Heterodimers ⁶³ ErbB4 Pathway ⁶³ Growth Hormone Signaling ⁶³ HMGB1 Pathway ⁶³ IL-4 Pathway ⁶³ LPS Stimulated MAPK Signaling ⁶³ PACAP Signaling ⁶³ PI3K Signaling in B-Lymphocyte ⁶³ Prolactin Signaling ⁶³ Thrombopoietin Pathway ⁶³ TREM1 Pathway ⁶³ UVC-Induced MAPK Signaling ⁶³	13.19	TP53 MYC JAK3 JAK1 FCER2 CR2
2	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.83	TP53 MYC JAK1 CCND1 ABL1
3	Pathways in cancer ³⁶	12.81	TP53 MYC JAK3 JAK1 CCND1 ABL1
4	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.75	TP53 TCL1A MYC MTCP1 JAK3 JAK1
5	Measles ³⁶ Show member pathways Epstein-Barr virus infection ³⁶ Influenza A ³⁶	12.68	TP53 MYC JAK3 JAK1 FCER2 CR2
6	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.6	TP53 MYC JAK1 CCND1 ABL1
7	NF-kappaB Signaling ⁴	12.54	ZAP70 JAK3 JAK1 CD38 CD19
8	MicroRNAs in cancer ³⁶	12.51	TP53 MYC CCND1 ATM ABL1
9	Prolactin Signaling Pathway ¹ ³⁶ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.45	ZAP70 MYC JAK1 CCND1
10	JAK-STAT signaling pathway ³⁶ Show member pathways B-Cell Development ⁶³ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶⁴ Interleukin-19, 20, 22, 24 ⁶⁵ Jak/STAT Signaling Pathway ⁶⁴ Type III interferon signaling ¹	12.38	MYC JAK3 JAK1 CCND1
11	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁶	12.37	TP53 MYC CCND1 ATM ABL1
12	Cell cycle ³⁶ ¹	12.35	TP53 MYC CCND1 ATM ABL1
13	Development IGF-1 receptor signaling ²³ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²³ Signal transduction AKT signaling ²³	12.32	TP53 MYC JAK3 JAK1 FCER2 CCND1
14	Viral carcinogenesis ³⁶	12.27	TP53 JAK3 JAK1 CCND1
15	Human T-cell leukemia virus 1 infection ³⁶	12.25	TP53 MYC JAK3 JAK1 CCND1 ATM
16	Immune response IFN alpha/beta signaling pathway ²³ Show member pathways Cytokine Network ⁶³ Interferon alpha/beta signaling ⁶⁵ Regulation of IFNA signaling ⁶⁵	12.24	TP53 MYC JAK1 ATM ABL1
17	p53 Signaling ⁶³ Show member pathways P53 Pathway ⁶⁶	12.22	TP53 CCND1 ATM ABL1
18	Colorectal Cancer Metastasis ⁶³	12.17	TP53 MYC JAK1 CCND1
19	Cellular senescence (KEGG) ³⁶	12.13	TP53 MYC CCND1 ATM
20	Integrated Breast Cancer Pathway ¹	11.99	TP53 MYC JAK1 CCND1 ATM ABL1
21	DNA Damage Response (only ATM dependent) ¹	11.95	TP53 MYC CCND1 ATM ABL1
22	Small cell lung cancer ³⁶	11.83	TP53 MYC CCND1
23	Retinoblastoma (RB) in Cancer ¹	11.82	TP53 MYC CCND1 ABL1
24	ATM Pathway ⁶³ Show member pathways ATM Signaling Pathway ¹	11.8	TP53 ATM ABL1
25	C-MYB transcription factor network ¹	11.74	MYC CCND1 ADA
26	Bladder cancer ³⁶ ¹	11.71	TP53 MYC CCND1
27	Regulation of Telomerase ¹	11.69	MYC CCND1 ATM ABL1
28	IL2 signaling events mediated by PI3K ¹ Show member pathways IL2 signaling events mediated by STAT5 ¹	11.67	MYC JAK3 JAK1
29	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.66	TP53 MYC ATM
30	IL4-mediated signaling events ¹	11.63	JAK3 JAK1 FCER2
31	p53 pathway ¹	11.6	TP53 ATM ABL1
32	Hepatitis C and Hepatocellular Carcinoma ¹	11.57	TP53 MYC JAK1 CCND1
33	Integrated Cancer Pathway ¹	11.5	TP53 MYC JAK1 ATM
34	Interleukin-4 and 13 signaling ⁶⁵	11.49	TP53 MYC JAK3 JAK1 FCER2 CCND1
35	IL-7 Signaling Pathway ¹ Show member pathways IL-9 Signaling Pathway ¹	11.47	MYC JAK3 JAK1 CCND1
36	DNA damage_ATM/ATR regulation of G1/S checkpoint ²³	11.45	TP53 MYC CCND1 ATM
37	Primary immunodeficiency ³⁶	11.36	ZAP70 JAK3 CD19 ADA
38	IL-10 Pathway ⁶³	11.34	MYC JAK1 CCND1
39	GADD45 Pathway ⁶³	11.29	TP53 CCND1 ATM
40	miRNAs involved in DNA damage response ¹	11.25	TP53 MYC CCND1 ATM ABL1
41	Telomere Extension by Telomerase ⁶³ Show member pathways XAV939 inhibits tankyrase, stabilizing AXIN ⁶⁵	11.18	MYC JAK3 JAK1
42	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶³	11.1	TP53 MYC ABL1
43	Hematopoietic cell lineage ³⁶	11.1	FCER2 CR2 CD7 CD5 CD38 CD19
44	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁵	11.05	TP53 MYC ATM ABL1

Sources

GO Terms for Prolymphocytic Leukemia

Cellular components related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016020	9.86	ZAP70 TP53 MYC JAK3 JAK1 FCER2
2	protein-containing complex	GO:0032991	9.1	TP53 TCL1A MYC MTCP1 CD19 ABL1

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	immune system process	GO:0002376	10.02	ZAP70 JAK3 CR2 CD7 CD19 ATM
2	negative regulation of apoptotic process	GO:0043066	10	TP53 TCL1A MYC CD38 ADA
3	cellular response to DNA damage stimulus	GO:0006974	9.97	TP53 MYC CCND1 ATM ABL1
4	regulation of apoptotic process	GO:0042981	9.88	TP53 JAK3 ATM ABL1
5	protein phosphorylation	GO:0006468	9.8	ZAP70 JAK3 JAK1 CCND1 ATM ABL1
6	regulation of cell cycle	GO:0051726	9.67	TP53 CCND1 ATM ABL1
7	positive regulation of response to DNA damage stimulus	GO:2001022	9.61	MYC ATM
8	regulation of cellular senescence	GO:2000772	9.6	TP53 ABL1
9	interleukin-15-mediated signaling pathway	GO:0035723	9.59	JAK3 JAK1
10	T cell activation	GO:0042110	9.58	ZAP70 CD7 ADA
11	interleukin-2-mediated signaling pathway	GO:0038110	9.57	JAK3 JAK1
12	positive regulation of alpha-beta T cell differentiation	GO:0046638	9.56	ZAP70 ADA
13	peptidyl-tyrosine phosphorylation	GO:0018108	9.56	ZAP70 JAK3 JAK1 ABL1
14	interleukin-9-mediated signaling pathway	GO:0038113	9.54	JAK3 JAK1
15	response to vitamin E	GO:0033197	9.52	CCND1 ADA
16	mitotic G1 DNA damage checkpoint	GO:0031571	9.51	TP53 CCND1
17	negative regulation of thymocyte apoptotic process	GO:0070244	9.49	JAK3 ADA
18	interleukin-21-mediated signaling pathway	GO:0038114	9.48	JAK3 JAK1
19	DNA damage induced protein phosphorylation	GO:0006975	9.46	ATM ABL1
20	cell cycle arrest	GO:0007050	9.46	TP53 MYC ATM ABL1
21	B cell proliferation involved in immune response	GO:0002322	9.43	CD19 ABL1
22	response to drug	GO:0042493	9.35	TP53 MYC CD38 CCND1 ADA
23	cytokine-mediated signaling pathway	GO:0019221	9.1	TP53 MYC JAK3 JAK1 FCER2 CCND1

Molecular functions related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	kinase activity	GO:0016301	9.73	ZAP70 JAK3 JAK1 CCND1 ATM ABL1
2	protein phosphatase binding	GO:0019903	9.5	TP53 JAK3 JAK1
3	protein tyrosine kinase activity	GO:0004713	9.46	ZAP70 JAK3 JAK1 ABL1
4	protein kinase activity	GO:0004672	9.43	ZAP70 JAK3 JAK1 CCND1 ATM ABL1
5	non-membrane spanning protein tyrosine kinase activity	GO:0004715	8.92	ZAP70 JAK3 JAK1 ABL1

Sources

Sources for Prolymphocytic Leukemia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia